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ABSTRACT 
Inhibiting the aggregation of amyloid-beta peptide (Aβ) is one therapeutic target for the 
prevention and treatment of Alzheimer’s disease. We have previously demonstrated that biphenyl-
3,3′,4,4′-tetrol (3,4-BPT) effectively abrogates Aβ aggregation at stoichiometric concentrations. To 
investigate molecular architecture and determine how the positioning of the hydroxyl hydrogen-
bond donors impacts inhibitor efficacy, we have synthesized four additional symmetrical 
biphenyltetrols (2,3-, 2,4- 2,5- and 3,5-BPT). We have evaluated these inhibitors by means of Congo 
red and Thioflavin T dye-binding assays to monitor Aβ aggregation as a function of time and to 
determine inhibitor IC50 values for reducing equilibrium levels of aggregation. 2,3- and 2,5-BPT 
were observed to be promising inhibitors of Aβ aggregation: we have qualitatively assessed their 
IC50 values to be approximately 7X and 3-4X, respectively. In contrast, 2,4- and 3,5-BPT showed 
little to no inhibition. Thus, 2,5-BPT was the most successful of the four inhibitors evaluated, 
however; it was not as effective as 3,4-BPT, studied previously (IC50 = 1.0 ± 0.3X). The four 
isomers we have characterized exhibit a range of IC50 values spanning more than one order of 
evaluation of the symmetrical biphenyltetrols, by methods including circular dichroism and 
transmission electron microscopy, which will afford greater insight into the Aβ assemblies formed in 
the presence and absence of inhibitors. These results will aid in the rational design of additional 
small-molecule aggregation inhibitors, including unsymmetrical biphenyltetrols and other 
architectures bearing hydroxyl substituents in those positions associated with the greatest inhibitory 
efficacy. 
 
INTRODUCTION 
Alzheimer’s disease (AD) is currently the sixth-leading cause of death in the United States.1 The 
aggregation of amyloid-β (Aβ), a peptide composed of 39-43 amino acids that is formed via proteolytic 
cleavage of the amyloid precursor protein (APP), is strongly linked to Alzheimer’s disease (AD).2 
Monomeric Aβ self-assembles to form an array of neurotoxic, β-structured aggregates, including soluble 
oligomers and insoluble fibrils. The fibrils have received great attention as the primary component of 
extracellular senile plaques characteristic of AD brain.3 Research efforts in the last 10-15 years have 
shown that smaller Aβ assemblies, specifically soluble oligomers, are more neurotoxic than insoluble 
fibrils.4 Therefore, the inhibition of Aβ aggregation is one therapeutic target for the prevention and 
treatment of AD.  
Previous research has hypothesized that small molecules can be designed and synthesized to 
bind to and inhibit the aggregation of Aβ. A number of small molecules containing oxygenated aromatic 
rings have demonstrated varying degrees of inhibitory activity.5,6 Reinke and Gestwicki previously 
evaluated curcumin (Figure 1) and curcumin-like molecules to identify structural features that are 
important for inhibition.7 They identified three major characteristics thought to be necessary for the 
inhibition of Aβ aggregation: 1) two aromatic groups, 2) one or more polar, hydrogen bonding 
substituents, and 3) a rigid linker of 8-16 Å.7 
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Figure 1. Curcumin 
 
To increase understanding of the structure-activity relationship between curcumin-related 
molecules and Aβ inhibition, we previously synthesized and evaluated three isomeric 
tetrahydroxyterphenyls and a tetrahydroxybiphenyl.8 The terphenyls (3,3”,4,4”-tetrahydroxy-o-terphenyl, 
3,3”,4,4”-tetrahydroxy-m-terphenyl, and 3,3”,4,4”-tetrahydroxy-p-terphenyl) were synthesized with the geometry 
around the phenyl linker in the ortho- (OTT), meta- (MTT), and para- (PTT) positions, respectively 
(Figure 2). These compounds were expected to inhibit Aβ aggregation because they contained two 
hydroxy-substituted aromatic groups connected by a rigid linker, in agreement with the structural 
features identified by Reinke and Gestwicki. 
 
           
 
Figure 2. Representative isomers of terphenyl-3,3",4,4"-tetrol (OTT, MTT, and PTT, respectively) 
 
The biphenyltetrol was synthesized to evaluate the need for the phenyl linker because, according 
to Reinke and Gestwicki, the molecule should fail to inhibit Aβ aggregation. All molecules were 
evaluated by means of a Congo red assay at a 10X concentration (1X = 25μM). Surprisingly, Stevens and 
coworkers concluded that 3,3’,4,4’-biphenyltetrol (3,4-BPT) was the most successful inhibitor with an 
IC50 value near 1.0X.8 These researchers suggested that the biphenyltetrol is more conformationally 
restricted than the inhibitors that were included in the Reinke and Gestwicki study; therefore, the 
characteristics Reinke and Gestwicki associated with inhibitory efficacy may not apply. 
3,4-BPT effectively abrogates Aβ aggregation at stoichiometric concentrations. This promising 
result inspired us to investigate this molecular architecture and determine how the positioning of 
hydroxyl hydrogen-bond donors impacts inhibitor efficacy. Toward that goal, we aimed to synthesize 
and evaluate five isomers of 3,4-BPT (Figure 3). The interaction occurring between monomeric Aβ and 
BPT is thought to be through hydrogen bonding; however, the mechanism is relatively unknown. The 
rearrangement of the hydroxyls around the aromatic rings will aid in determining which positions are 
most favorable for inhibition. Currently, we have synthesized and characterized 2,3-, 2,4-, 2,5-, and 3,5-
BPT. There have been limitations in synthesizing 2,6-BPT, in which steric hindrance is thought to be 
preventing the formation of the required intermediate; however, the complete synthesis of 2,6-BPT is 
currently in progress. 
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Figure 3. Structures of biphenyl-2,2',3,3'-tetrol (2,3-BPT), biphenyl-2,2',4,4'-tetrol (2,4-BPT), 
biphenyl-2,2',5,5'-tetrol (2,5-BPT), biphenyl 2,2',6,6'-tetrol (2,6-BPT), biphenyl-3,3',4,4'-tetrol (3,4-BPT), and 
biphenyl-3,3',5,5'-tetrol (3,5-BPT), respectively. 
 
The four isomeric compounds were evaluated by means of Thioflavin T and Congo red dye-
binding assays. The dyes selectively bind β-sheet structures and allow Aβ aggregation to be monitored as 
a function of time for samples with and without inhibitor. We have employed Congo red assays to 
determine inhibitor IC50 values and thus quantify the efficacy of the symmetrical molecules. When the 
evaluation is complete, we expect to report a range of inhibitor IC50 values that will support our 
hypothesis that hydroxyl positioning has a measurable effect on inhibitor activity. These results may 
impact the rational design of future inhibitors.  
 
METHODS 
Disaggregation of Aβ 
Lyophilized Aβ(1-40) peptide was purchased from AnaSpec, Inc. and stored at -20 °C. The 
peptide was brought to room temperature and dissolved in hexafluoroisopropnal (HFIP), resulting in a 
peptide concentration of 5 mg/mL. The vial was sealed to prevent evaporation loss and remained in a 
hood overnight. The following day, HFIP was evaporated under nitrogen for at least 1 hour, leaving 
behind a peptide film. The film was dissolved and thoroughly mixed in dimethyl sulfoxide (DMSO) for 
20 minutes to obtain a final peptide concentration of 2 mM. Aliquots of the peptide solution were 
transferred to microcentrifuge tubes and stored in a -80 °C freezer. 
Thioflavin T (ThT) Assay 
Aβ(1-40) aliquots in DMSO were brought to room temperature and diluted to 50 μM with 25 
mM phosphate buffer solution (25 mM sodium phosphate, 120 mM NaCl,  1.25 µM Thioflavin T, and 
0.02% sodium azide, pH 7.4) maintaining 10% DMSO by volume. Inhibitor samples were prepared 
similarly with the addition of a biphenyltetrol, 10 mM in DMSO, at varying volumes to obtain the 
desired inhibitor concentration (0-500 μM, i.e., 0-10X). Samples with and without inhibitor were 
incubated at 37 °C and shaken at 1500 RPM to promote aggregation. Each sample was removed from 
the incubator/shaker periodically and loaded into a 1-cm path length quartz cuvette. Fluorescence 
spectra were acquired with an excitation wavelength of 450 nm and emission wavelengths of 460-600 
nm. Samples were returned to the incubator/shaker and the cuvette was rinsed between samples 3 times 
with distilled water. The peak areas from the ThT spectra were integrated and plotted as a percentage of 
the control sample as a function of time.  
 
  
80 
 
Congo Red (CR) Assay 
Aβ(1-40) aliquots in DMSO were brought to room temperature and diluted to 50 μM with 
phosphate buffered saline, (PBS, 1X concentration: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, and 
1.47 mM KH2PO4, pH 7.4) maintaining 10% DMSO by volume. Inhibitor samples were prepared 
similarly with the addition of a biphenyltetrol, 10 mM in DMSO, at varying volumes to obtain the 
desired inhibitor concentration (0-500 μM, i.e., 0-10X). A CR stock solution of 50 μM was made in 1X 
PBS. Samples with and without inhibitor were incubated at 37 °C and shaken at 1500 RPM to promote 
aggregation. An aliquot of sample was removed from the incubator/shaker periodically and combined 
with an equal volume of 50 μM CR, diluting the CR and A concentrations to 25 μM each. The 
CR/sample solution was mixed 20 times to ensure proper association between CR and Aβ and loaded in 
a 1-cm path length quartz cuvette; the absorbance was measured at the wavelengths of 403 and 541 nm. 
Between samples, the cuvette was rinsed 3 times with a 90% 1X PBS/10% DMSO solution. The 
concentrations of bound complex ([CR-Aβ]) for each sample, used to monitor Aβ aggregation, were 
calculated from the absorbance values and extinction coefficients at the measured wavelengths, 
according to Eq. 1.9 The [CR-A] for each sample was monitored and plotted as a function of time.  
[CR-Aβ] = (A541/47,800) - (A403/38,100)          (1) 
IC50 Determination 
A range of inhibitor concentrations were evaluated to determine the overall inhibitory efficacy of 
each biphenyltetrol. Inhibitor samples were prepared as described above, with the desired BPT 
concentrations ranging from 25 μM to 500 μM (0.5X-10X). Control and inhibitor samples were 
incubated at 37 °C and shaken at 1500 RPM to promote aggregation. When aggregation of the control 
reached equilibrium, aliquots of the various inhibitor samples were taken in random order to measure 
[CR-Aβ]. Collecting data at equilibrium is favorable for the day-to-day reproducibility of results. 
Inhibitor concentrations were quantitatively compared by calculating respective [CR-Aβ] values as a 
percent of control. These responses were plotted versus the inhibitor concentration on a semi-log plot. 
The IC50 is the concentration at which aggregation is inhibited by 50 %. 
 
RESULTS & DISCUSSION 
Our preliminary data from the spectroscopic evaluations of four symmetrical biphenyltetrols 
show 2,4- and 3,5-BPT to be poor inhibitors of Aβ aggregation, while 2,3- and 2,5-BPT inhibit 
equilibrium levels of aggregation to a quantifiable degree. ThT and CR results were consistent, which 
allowed for verification of inhibitor efficacy by two methods and ensured accurate data collection.  
 
  
Figure 4. ThT (left) and CR (right) assay results for control vs. 10X 2,4-BPT 
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The ThT and CR data for 2,4-BPT at 10X concentration, Figure 4, illustrate the consistency of results 
between assays. At equilibrium, there is little difference between the control and 2,4-BPT samples, which 
indicates little to no inhibition.  
 
 
 
Figure 5. Congo red assay results for 3,5-BPT (10X concentration, squares) versus inhibitor-free control 
(diamonds). At 10X, 3,5-BPT demonstrates little inhibitory activity against Aβ aggregation. 
 
We saw similar results with 3,5-BPT, Figure 5, where there is little difference between the control and 
3,5-BPT samples at equilibrium. At 10X concentration, neither 2,4- nor 3,5-BPT demonstrate inhibitory 
properties against Aβ aggregation.  
 
 
 
Figure 6. Congo red assay results for 2,3-BPT (10X, squares) versus inhibitor-free control (diamonds). In the 
presence of 10X 2,3-BPT, less CR-A complex is formed, indicating some degree of inhibition. 
 
There is a greater difference, at equilibrium, between the control and 10X 2,3-BPT samples which 
indicates some degree of inhibition (Figure 6). Similar results were seen with 10X 2,5-BPT in which the 
molecule demonstrated inhibitory properties against Aβ aggregation (Figure 7). 
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Figure 7. Congo red assay results for 2,5-BPT (10X, squares) show much less CR-A formation compared to 
the control (diamonds), which indicates significant inhibition. 
 
We can conclude from our preliminary data that altering the positions of the hydroxyl groups 
around the aromatic rings has an effect on inhibitor efficacy. We determined the 2,4- and 3,5- hydroxyl 
positions to be unfavorable for inhibition, whereas the 2,3- and 2,5- positions appear to be more 
favorable for hydrogen-bonding interactions with Aβ. 
As a further evaluation of inhibitor efficacy, we investigated IC50 values for 2,3- and 2,5-BPT. 
From preliminary results, we qualitatively determined 2,3- and 2,5-BPT to have IC50 values of about 7X 
and 3-4X, respectively. Based on our previous ThT and CR results, the IC50 values of 2,4- and 3,5-BPT 
are expected to be greater than 10X. Thus, 2,5-BPT was the most effective inhibitor of the four 
molecules evaluated, but it did not match the efficacy of 3,4-BPT, for which the IC50 is 1.0 X.3 The four 
isomers we have characterized exhibit a range of IC50 values spanning more than one order of 
magnitude, likely due to varying abilities to bind to A assemblies. The range of inhibitory activity 
supports our hypothesis that altering positions of the hydroxyl groups affects inhibitor efficacy.  
Future work will involve further evaluation of these symmetrical biphenyltetrols, by methods 
including circular dichroism and transmission electron microscopy, which will afford greater insight into 
the A assemblies formed in the presence and absence of inhibitors. As a result of knowledge gained 
from preliminary studies of symmetrical biphenyltetrols, we have also synthesized two unsymmetrical 
biphenyltetrols, in which the hydroxyl groups occupy different positions on each ring (Figure 8): a 
hybrid of 3,4- and 2,3-BPT (biphenyl-2,3’,4’,3-tetrol, 3,4,2,3-BPT) as well as a hybrid of 3,4- and 2,5-BPT 
(biphenyl-2,3’,4’,5-tetrol, 3,4,2,5-BPT). These molecules will allow us to evaluate how the change in 
positioning of hydroxyl hydrogen-bond donors around the phenyl rings impacts inhibitor efficacy against 
Aβ aggregation. 
                                  
Figure 8. Structures of biphenyl-2,3’,4’,3-tetrol (3,4,2,3-BPT, left) and biphenyl-2,3’,4’,5-tetrol (3,4,2,5-BPT, 
right) 
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